(Q42751053)

6 November 2017

title

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial (English)

1 reference

6 November 2017

main subject

phase II clinical trial

0 references

1 reference

1

Robert A Hauser

1 reference

6 November 2017

Marc Cantillon

2

1 reference

6 November 2017

Emmanuelle Pourcher

3

1 reference

6 November 2017

Federico Micheli

4

1 reference

6 November 2017

Vincent Mok

5

1 reference

6 November 2017

Marco Onofrj

6

1 reference

6 November 2017

Susan Huyck

7

1 reference

6 November 2017

Kenneth Wolski

8

1 reference

6 November 2017

publication date

1 March 2011

1 reference

6 November 2017

1 reference

6 November 2017

volume

10

1 reference

6 November 2017

issue

3

1 reference

6 November 2017

page(s)

221-229

1 reference

Adverse events from the treatment of Parkinson's disease.

6 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Adenosine A2A receptors and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Parkinson's disease home diary: further validation and implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Average Partial Association in Three-Way Contingency Tables: A Review and Discussion of Alternative Tests

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Adenosine receptors and the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Caffeine and progression of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970012-6

7 January 2021

10.1016/S1474-4422(11)70012-6

Identifiers

DOI

1 reference

release_iwrw75ufdjctpa2iguocnwhbuu

6 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iwrw75ufdjctpa2iguocnwhbuu

24 November 2022

mapped directly with Wikidata item

1 reference